샘플 요청 목록

 카트 문의
시장보고서
상품코드
2067552

MRI 조영제 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 제품 유형별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

MRI Contrast Media Agents Market Size, Share & Trends Analysis Report By Product, By Type, By Application, By End-use, By Region, And Segment Forecasts, 2026 - 2033
발행일: | 리서치사: 구분자 Grand View Research | 페이지 정보: 영문 120 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




가격
Unprintable PDF & Excel (Single User License) help
보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.
US $ 5,950 금액 안내 화살표 ￦ 9,326,000
Printable PDF & Excel (5-User License) help
보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.
US $ 6,950 금액 안내 화살표 ￦ 10,894,000
Printable PDF & Excel (Enterprise License) help
PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.
US $ 8,950 금액 안내 화살표 ￦ 14,029,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

MRI 조영제 시장 개요

세계의 MRI 조영제 시장 규모는 2025년에 23억 9,000만 달러로 추정되며, 2033년에 43억 3,000만 달러에 달할 것으로 예측됩니다.

2026-2033년 연평균 성장률(CAGR) 7.15%로 성장할 것으로 전망됩니다. 이 시장은 주로 암, 신경계 질환, 심혈관 질환 등 만성질환의 유병률 증가에 힘입어 성장하고 있으며, 이러한 질환을 정확하게 진단하기 위해서는 첨단 영상 기술이 필요합니다.

비침습적이라는 특성과 뛰어난 연조직 시각화 능력에 힘입어 MRI 검사의 도입이 확대되고 있는 점도 수요를 더욱 끌어올리고 있습니다. 또한 보다 안전하고 표적 특이성이 높은 제제를 포함한 조영제의 기술적 발전이 시장 성장을 지원하고 있습니다.

암, 신경계 질환, 심혈관 질환 등 만성질환이 전 세계에서 증가하고 있는 만큼, 정확하고 조기 진단을 가능하게 하는 영상 진단에 대한 수요가 크게 높아지고 있습니다. MRI 검사, 특히 조영제를 사용한 검사는 종양 발견, 뇌 이상 평가, 혈관 상태의 정밀 평가에 있으며, 매우 중요한 역할을 하고 있습니다. 질환의 유병률이 높아짐에 따라 진단, 병기 분류, 치료 경과 모니터링을 위한 반복 영상 촬영의 필요성이 커지고 있으며, 이는 조영제를 이용한 MRI의 활용을 더욱 촉진하고 있습니다. 이러한 추세는 MRI 조영제 시장의 지속적인 성장에 직접적으로 기여하고 있습니다.

전 세계에서 신경계 질환의 부담이 커지고 있습니다.

전 세계 인구의 3명 중 1명 이상이 일생 동안 어떤 형태의 신경질환이나 정신 질환을 겪을 것으로 예상되며, 그 영향을 받는 사람은 약 34억 명에 달합니다.

신경계 질환은 전 세계에서 장애와 삶의 질 저하의 주요 원인이 되고 있습니다.

매년 약 1,100만 명의 사망이 신경계 질환에 기인하고 있습니다.

치매를 앓는 사람의 수는 2030년까지 7,800만 명, 2050년까지 1억 3,900만 명에 달할 것으로 예측됩니다.

뇌 관련 질환으로 인한 부담은 암과 심혈관 질환을 합친 것보다 더 큽니다.

조영제의 기술적 발전은 안전성과 진단 정확도를 모두 향상시킴으로써 MRI 조영제 시장을 크게 견인하고 있습니다. 대환형 가돌리늄계 조영제 및 새롭게 등장한 비가돌리늄계 대체제의 개발로 인해 독성 및 체내 잔류에 대한 우려가 해소되면서, 임상 현장에서의 보다 광범위한 채택이 촉진되고 있습니다. 이러한 혁신을 통해 영상의 선명도가 향상되고, 복잡한 병변을 보다 정확하게 탐지할 수 있게 되어 조영제 MRI의 활용 확대를 지원하고 있습니다. 예를 들어 2026년 2월 NCBI에 발표된 총설에 따르면 MRI 조영제의 발전은 높은 이완율을 가진 가돌리늄계 조영제(가도피클레놀, 가도쿠아트란, 기타), 망간계 조영제, 산화철 나노입자에 초점을 맞추고 있으며, 이들이 영상 성능과 안전성 프로파일의 향상에 기여하고 있음을 강조했습니다. 이러한 혁신에 더해, 표적 지향형 및 차세대 조영제 제제의 개발로 인해 진단 정확도가 향상되고 임상 적용 범위가 확대되면서, 그 결과 MRI 조영제 시장의 성장이 촉진되고 있습니다.

또한 2026년 4월, GE 헬스케어는 망간계 MRI 조영제 ‘망가시클라놀’에 대한 전 세계 2/3상 임상시험 ‘LUMINA’의 시작을 발표했으며, 메이요 클리닉에서 첫 환자에게 투여가 이루어졌습니다. 미국 식품의약국(FDA)으로부터 패스트트랙 지정을 받은 이 임상시험용 약물은, 성인 및 소아 환자의 중추신경계 전반에 걸친 병변 탐지 및 전신 영상 촬영 분야에서 가돌리늄계 조영제의 대체 후보로 평가받고 있습니다.

GE 헬스케어의 의약품·진단 부문 최고 의료 책임자인 지트 사이니 박사는 다음과 같이 말했습니다. "기존의 가돌리늄계 조영제에는 가돌리늄의 체내 잔류와 관련된 안전 주의사항이 기재되어 있습니다. 이에 비해, 망가시클라놀은 취약한 환자나 여러 차례의 스캔이 필요한 환자를 포함한 광범위한 환자층에게, 동등한 진단 성능을 유지하면서 대체 수단이 될 가능성이 있습니다. FDA의 패스트트랙 지정은 망가시클라놀의 잠재적 중요성을 인정하는 것이며, 환자를 위해 해당 약물의 개발을 추진하려는 당사의 노력과 일치합니다. '

GE 헬스케어의 사장 겸 CEO인 피터 알두이니 씨는 "영상 진단에 대한 수요가 지속적으로 증가하는 가운데, 당사는 환자의 요구에 더 잘 부응하기 위해 조영제 파이프라인 개발을 지속적으로 추진하고 있습니다"라고 말했습니다. "망가시클라놀은 MR 영상 시장에 혁신을 가져오고 공급망의 탄력성을 높일 잠재력을 지니고 있으며, 이번 임상적 성과는 조영제 부문에서 GE 헬스케어의 리더십을 한층 더 공고히 할 것입니다. " '

또한 첨단 영상 기술의 발전 역시 MRI 조영제 시장의 또 다른 성장 동력이 되고 있습니다. 고자기장 MRI 시스템의 도입과 방사선과 네트워크의 확대로 인해 검사 건수가 증가하고 있기 때문입니다. 영상 진단 능력의 향상과 비침습적이며 고해상도 진단으로의 전환에 따라 조영제 MRI의 활용이 확대되고 있습니다. 이러한 추세는 신흥 시장에서 특히 두드러지며, 의료 인프라의 개선에 힘입어 첨단 영상 진단 서비스에 대한 접근성이 빠르게 확대되고 있습니다.

자주 묻는 질문

  • MRI 조영제 시장 규모는 어떻게 예측되나요?
  • MRI 조영제 시장의 성장 요인은 무엇인가요?
  • 신경계 질환의 전 세계적인 영향은 어떤가요?
  • MRI 조영제의 기술적 발전은 어떤 영향을 미치고 있나요?
  • GE 헬스케어의 새로운 MRI 조영제는 어떤 특징이 있나요?
  • MRI 조영제 시장의 성장에 기여하는 첨단 기술은 무엇인가요?

목차

제1장 조사 방법과 범위

제2장 개요

제3장 MRI 조영제 시장 : 변수, 동향, 범위

제4장 MRI 조영제 시장 : 제품별, 추정·동향 분석

제5장 MRI 조영제 시장 : 유형별, 추정·동향 분석

제6장 MRI 조영제 시장 : 용도별, 추정·동향 분석

제7장 MRI 조영제 시장 : 최종 용도별, 추정·동향 분석

제8장 MRI 조영제 시장 : 지역별, 추정·동향 분석

제9장 경쟁 구도

KSA 26.06.30

MRI Contrast Media Agents Market Summary

The global MRI contrast media agents market size was estimated at USD 2.39 billion in 2025 and is projected to reach USD 4.33 billion by 2033, growing at a CAGR of 7.15% from 2026 to 2033. The market is primarily driven by the rising prevalence of chronic diseases such as cancer, neurological disorders, and cardiovascular conditions, which require advanced imaging for accurate diagnosis.

The increasing adoption of MRI procedures, driven by their non-invasive nature and superior soft-tissue visualization, is further boosting demand. In addition, ongoing technological advancements in contrast agents, including safer and more targeted formulations, are supporting market growth.

The rising global burden of chronic diseases such as cancer, neurological disorders, and cardiovascular conditions are significantly increasing the demand for accurate and early diagnostic imaging. MRI procedures, particularly those using contrast agents, play a critical role in detecting tumors, assessing brain abnormalities, and evaluating vascular conditions with high precision. As disease prevalence grows, the need for repeated imaging for diagnosis, staging, and treatment monitoring further drives the utilization of contrast-enhanced MRI. This trend is directly contributing to the sustained expansion of the MRI contrast media agents market.

Rising Global Burden of Neurological Disorders

More than one in three people globally are expected to experience a neurological or psychiatric disorder during their lifetime, affecting approximately 3.4 billion individuals.

Neurological disorders are a leading cause of disability and reduced quality of life worldwide.

Around 11 million deaths each year are attributed to neurological conditions.

The number of people living with dementia is projected to reach 78 million by 2030 and 139 million by 2050.

The burden of brain-related disorders exceeds that of cancer and cardiovascular diseases combined.

Technological advancements in contrast agents are significantly driving the MRI contrast media market by improving both safety and diagnostic precision. The development of macrocyclic gadolinium-based agents and emerging non-gadolinium alternatives is addressing concerns about toxicity and retention, thereby encouraging wider clinical adoption. These innovations are enhancing image clarity and enabling more accurate detection of complex conditions, supporting increased utilization of contrast-enhanced MRI. For instance, in February 2026, a review published on NCBI highlighted that advancements in MRI contrast agents are centered on high-relaxivity gadolinium-based agents (e.g., gadopiclenol, gadoquatrane), manganese-based agents, and iron oxide nanoparticles, which improve imaging performance and safety profiles. These innovations, along with the development of targeted and next-generation contrast formulations, are enhancing diagnostic precision and expanding clinical applications, thereby driving growth in the MRI contrast media agents market.

Furthermore, in April 2026, GE HealthCare announced the initiation of its global Phase 2/3 LUMINA trial, with the first patient dosed for the manganese-based MRI contrast agent mangaciclanol at Mayo Clinic. The investigational agent, granted Fast Track designation by the U.S. Food and Drug Administration, is being evaluated as a potential alternative to gadolinium-based agents for detecting lesions across the central nervous system and whole-body imaging in adult and pediatric patients.

Dr. Jit Saini, Chief Medical Officer, Pharmaceutical Diagnostics, GE HealthCare, said, "Existing gadolinium-based contrast agents carry safety language associated with gadolinium retention. In comparison, mangaciclanol could offer an alternative for broad patient groups, including vulnerable patients and those requiring multiple scans, while still offering similar diagnostic performance. The FDA Fast Track designation recognizes the potential significance of mangaciclanol and aligns with our focus on advancing its development for patients."

"As demand for diagnostic imaging continues to rise, we continue to advance our imaging agent pipeline to better meet the needs of patients," said Peter Arduini, President and CEO, GE HealthCare. "This clinical milestone builds on GE HealthCare's leadership in contrast media, as mangaciclanol has the potential to transform the MR imaging market and strengthen the resiliency of its supply chain."

Moreover, growth in advanced diagnostic imaging is another driver of the MRI contrast media/agents market, as the installation of high-field MRI systems and the expansion of radiology networks increase scan volumes. Enhanced imaging capabilities and a shift toward non-invasive, high-resolution diagnostics are encouraging greater use of contrast-enhanced MRI. This trend is particularly strong in emerging markets, where improving healthcare infrastructure is accelerating access to advanced imaging services.

Global MRI Contrast Media Agents Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global MRI contrast media agents market report on the basis of product, type, application, end-use, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Paramagnetic Agents
  • Superparamagnetic Agents
  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Clinical
  • Preclinical
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Gastrointestinal
  • Intravenous
  • Hepatobiliary
  • Neurological Imaging
  • Others
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Imaging Centers
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Product
    • 1.1.2. Type
    • 1.1.3. Application
    • 1.1.4. End Use
    • 1.1.5. Regional scope
    • 1.1.6. Estimates and forecast timeline
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
  • 1.5. Details of primary research
    • 1.5.1. Data for primary interviews in North America
    • 1.5.2. Data for primary interviews in Europe
    • 1.5.3. Data for primary interviews in Asia Pacific
    • 1.5.4. Data for primary interviews in Latin America
    • 1.5.5. Data for Primary interviews in MEA
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
      • 1.7.1.1. Approach 1: Commodity flow approach
    • 1.7.2. Volume price analysis (Model 2)
      • 1.7.2.1. Approach 2: Volume price analysis
  • 1.8. Research Scope and Assumptions
    • 1.8.1. List of Secondary Sources
    • 1.8.2. List of Primary Sources
    • 1.8.3. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. MRI Contrast Media Agents Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Drivers Analysis
      • 3.2.1.1. Rising prevalence of chronic diseases
      • 3.2.1.2. Increasing demand for advanced diagnostic imaging
      • 3.2.1.3. Growing adoption of MRI procedures globally
      • 3.2.1.4. Technological advancements in contrast agents
    • 3.2.2. Market Restraints Analysis
      • 3.2.2.1. Stringent regulatory approval processes
      • 3.2.2.2. High cost of MRI procedures and contrast agents
    • 3.2.3. Market Opportunity Analysis
      • 3.2.3.1. Development of non-gadolinium-based contrast agents
      • 3.2.3.2. Advancements in targeted and organ-specific imaging agents
      • 3.2.3.3. Expansion in emerging markets
      • 3.2.3.4. Increasing adoption of personalized and precision medicine
    • 3.2.4. Market Challenge Analysis
      • 3.2.4.1. Safety and toxicity concerns associated with contrast agents
      • 3.2.4.2. Availability of alternative imaging modalities (CT, ultrasound)
  • 3.3. MRI Contrast Media Agents Market Analysis Tools
    • 3.3.1. Porter's Analysis
      • 3.3.1.1. Bargaining power of the suppliers
      • 3.3.1.2. Bargaining power of the buyers
      • 3.3.1.3. Threats of substitution
      • 3.3.1.4. Threats from new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental landscape
      • 3.3.2.5. Legal landscape

Chapter 4. MRI Contrast Media Agents Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global MRI Contrast Media Agents Market: Product Movement Analysis, 2025 & 2033 (USD Million)
  • 4.3. Global MRI Contrast Media Agents Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
    • 4.3.1. Paramagnetic Agents
      • 4.3.1.1. Paramagnetic agents market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.3.2. Superparamagnetic Agents
      • 4.3.2.1. Superparamagnetic agents market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. MRI Contrast Media Agents Market: Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global MRI Contrast Media Agents Market: Type Movement Analysis, 2025 & 2033 (USD Million)
  • 5.3. Global MRI Contrast Media Agents Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
    • 5.3.1. Clinical
      • 5.3.1.1. Clinical market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.3.2. Preclinical
      • 5.3.2.1. Preclinical market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. MRI Contrast Media Agents Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global MRI Contrast Media Agents Market: Application Movement Analysis, 2025 & 2033 (USD Million)
  • 6.3. Global MRI Contrast Media Agents Market Size & Trend Analysis, by Application , 2021 to 2033 (USD Million)
    • 6.3.1. Gastrointestinal
      • 6.3.1.1. Gastrointestinal market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.3.2. Intravenous
      • 6.3.2.1. Intravenous market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.3.3. Hepatobiliary
      • 6.3.3.1. Hepatobiliary market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.3.4. Neurological Imaging
      • 6.3.4.1. Neurological imaging market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.3.5. Others
      • 6.3.5.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. MRI Contrast Media Agents Market: End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global MRI Contrast Media Agents Market: End Use Movement Analysis, 2025 & 2033 (USD Million)
  • 7.3. Global MRI Contrast Media Agents Market Size & Trend Analysis, by End Use 2021 to 2033 (USD Million)
    • 7.3.1. Hospitals
      • 7.3.1.1. Hospitals market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. Imaging Centers
      • 7.3.2.1. Imaging centers market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. MRI Contrast Media Agents Market: Regional Estimates & Trend Analysis by Product, Type, Application , and End Use

  • 8.1. Regional Dashboard
  • 8.2. Market Size and Trend Analysis, 2021 to 2033
  • 8.3. North America
    • 8.3.1. North America MRI contrast media agents market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.3.2. U.S.
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Competitive scenario
      • 8.3.2.3. Regulatory framework
      • 8.3.2.4. Reimbursement scenario
      • 8.3.2.5. U.S. MRI contrast media agents market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.3.3. Canada
      • 8.3.3.1. Key country dynamics
      • 8.3.3.2. Competitive scenario
      • 8.3.3.3. Regulatory framework
      • 8.3.3.4. Reimbursement scenario
      • 8.3.3.5. Canada MRI contrast media agents market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.3.4. Mexico
      • 8.3.4.1. Key country dynamics
      • 8.3.4.2. Competitive scenario
      • 8.3.4.3. Regulatory framework
      • 8.3.4.4. Reimbursement scenario
      • 8.3.4.5. Mexico MRI contrast media agents market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.4. Europe
    • 8.4.1. Europe MRI contrast media agents market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.4.2. UK
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Competitive scenario
      • 8.4.2.3. Regulatory framework
      • 8.4.2.4. Reimbursement scenario
      • 8.4.2.5. UK MRI contrast media agents market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.4.3. Germany
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Competitive scenario
      • 8.4.3.3. Regulatory framework
      • 8.4.3.4. Reimbursement scenario
      • 8.4.3.5. Germany MRI contrast media agents market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.4.4. France
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Competitive scenario
      • 8.4.4.3. Regulatory framework
      • 8.4.4.4. Reimbursement scenario
      • 8.4.4.5. France MRI contrast media agents market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.4.5. Italy
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Competitive scenario
      • 8.4.5.3. Regulatory framework
      • 8.4.5.4. Reimbursement scenario
      • 8.4.5.5. Italy MRI contrast media agents market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.4.6. Spain
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Competitive scenario
      • 8.4.6.3. Regulatory framework
      • 8.4.6.4. Reimbursement scenario
      • 8.4.6.5. Spain MRI contrast media agents market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.4.7. Sweden
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Competitive scenario
      • 8.4.7.3. Regulatory framework
      • 8.4.7.4. Reimbursement scenario
      • 8.4.7.5. Sweden MRI contrast media agents market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.4.8. Denmark
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Competitive scenario
      • 8.4.8.3. Regulatory framework
      • 8.4.8.4. Reimbursement scenario
      • 8.4.8.5. Denmark MRI contrast media agents market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.4.9. Norway
      • 8.4.9.1. Key country dynamics
      • 8.4.9.2. Competitive scenario
      • 8.4.9.3. Regulatory framework
      • 8.4.9.4. Reimbursement scenario
      • 8.4.9.5. Norway MRI contrast media agents market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Asia Pacific MRI contrast media agents market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.5.2. China
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Competitive scenario
      • 8.5.2.3. Regulatory framework
      • 8.5.2.4. Reimbursement scenario
      • 8.5.2.5. China MRI contrast media agents market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.5.3. Japan
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Competitive scenario
      • 8.5.3.3. Regulatory framework
      • 8.5.3.4. Reimbursement scenario
      • 8.5.3.5. Japan MRI contrast media agents market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.5.4. India
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Competitive scenario
      • 8.5.4.3. Regulatory framework
      • 8.5.4.4. Reimbursement scenario
      • 8.5.4.5. India MRI contrast media agents market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.5.5. South Korea
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Competitive scenario
      • 8.5.5.3. Regulatory framework
      • 8.5.5.4. Reimbursement scenario
      • 8.5.5.5. South Korea MRI contrast media agents market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.5.6. Australia
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Competitive scenario
      • 8.5.6.3. Regulatory framework
      • 8.5.6.4. Reimbursement scenario
      • 8.5.6.5. Australia MRI contrast media agents market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.5.7. Thailand
      • 8.5.7.1. Key country dynamics
      • 8.5.7.2. Competitive scenario
      • 8.5.7.3. Regulatory framework
      • 8.5.7.4. Reimbursement scenario
      • 8.5.7.5. Thailand MRI contrast media agents market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Latin America MRI contrast media agents market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.6.2. Brazil
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Competitive scenario
      • 8.6.2.3. Regulatory framework
      • 8.6.2.4. Reimbursement scenario
      • 8.6.2.5. Brazil MRI contrast media agents market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.6.3. Argentina
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Competitive scenario
      • 8.6.3.3. Regulatory framework
      • 8.6.3.4. Reimbursement scenario
      • 8.6.3.5. Argentina MRI contrast media agents market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.7. Middle East and Africa
    • 8.7.1. Middle East and Africa MRI contrast media agents market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.7.2. South Africa
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Competitive scenario
      • 8.7.2.3. Regulatory framework
      • 8.7.2.4. Reimbursement scenario
      • 8.7.2.5. South Africa MRI contrast media agents market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.7.3. Saudi Arabia
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Competitive scenario
      • 8.7.3.3. Regulatory framework
      • 8.7.3.4. Reimbursement scenario
      • 8.7.3.5. Saudi Arabia MRI contrast media agents market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.7.4. UAE
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Competitive scenario
      • 8.7.4.3. Regulatory framework
      • 8.7.4.4. Reimbursement scenario
      • 8.7.4.5. UAE MRI contrast media agents market estimates and forecasts, 2021 - 2033 (USD Million)
    • 8.7.5. Kuwait
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Competitive scenario
      • 8.7.5.3. Regulatory framework
      • 8.7.5.4. Reimbursement scenario
      • 8.7.5.5. Kuwait MRI contrast media agents market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis by Key Market Participants
  • 9.2. Company Categorization
  • 9.3. Company Market Share Analysis, 2025
  • 9.4. Company Heat Map Analysis
  • 9.5. Strategy Mapping
    • 9.5.1. Expansion
    • 9.5.2. Mergers & Acquisition
    • 9.5.3. Partnerships & Collaborations
    • 9.5.4. New Product Launches
    • 9.5.5. Research And Development
    • 9.5.6. Company Profiles
    • 9.5.7. GE Healthcare
      • 9.5.7.1. Company overview
      • 9.5.7.2. Financial performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic initiatives
    • 9.5.8. Bayer AG
      • 9.5.8.1. Company overview
      • 9.5.8.2. Financial performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic initiatives
    • 9.5.9. Guerbet GmbH
      • 9.5.9.1. Company overview
      • 9.5.9.2. Financial performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic initiatives
    • 9.5.10. Bracco Imaging Spa
      • 9.5.10.1. Company overview
      • 9.5.10.2. Financial performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic initiatives
    • 9.5.11. Vitalquan, LLC
      • 9.5.11.1. Company overview
      • 9.5.11.2. Financial performance
      • 9.5.11.3. Product Benchmarking
      • 9.5.11.4. Strategic initiatives
    • 9.5.12. Miltenyi Biotec B.V. & Co. Kg
      • 9.5.12.1. Company overview
      • 9.5.12.2. Financial performance
      • 9.5.12.3. Product Benchmarking
      • 9.5.12.4. Strategic initiatives
    • 9.5.13. Beijing Beilu Pharmaceutical Co., Ltd.
      • 9.5.13.1. Company overview
      • 9.5.13.2. Financial performance
      • 9.5.13.3. Product Benchmarking
      • 9.5.13.4. Strategic initiatives
    • 9.5.14. JB Pharma
      • 9.5.14.1. Company overview
      • 9.5.14.2. Financial performance
      • 9.5.14.3. Product Benchmarking
      • 9.5.14.4. Strategic initiatives
×

원하시는 정보를 찾아 드릴까요?

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
kr-info@giikorea.co.kr
문의하기